MagBiosense, Inc. is a private medical device company focused on the development of breakthrough diagnostic device and assays, offering laboratory-quality sensitivity and the rapid results and ease of use of a point-of-care system. The company’s core technology eliminates the need for additional steps in the detection process, thereby allowing a simple, one-step process in a point-of-care setting.

Initially, MagBiosense focuses its development on highly sensitive and specific serological assays for infectious disease, such as Zika, dengue, and West-Nile viruses. Clinical trials that are being conducted at Sheba Medical Center show that the MMB-based Zika IgM/IgG assays have much higher sensitivity (88–97%) and specificity (100%) than Euroimmun ELISA. Moreover, the MMB-based assays have 90% fewer false positive results than the Euroimmun ELISA see more.... In addition, using high sensitivity detection of cardiac troponin I, MagBiosense develops a rapid assay for diagnosis and rule out of heart attacks at the Emergency Departments see more...